SeekingAlpha · Aug 7, 2026
Immunocore Holdings plc 2026 Q2 - Results - Earnings Call Presentation
2026-08-07. The following slide deck was published by Immunocore Holdings plc in conjunction with their 2026 Q2 earnings call.
IM
NASDAQ · IMCR
Immunocore Holdings plc
Healthcare · Biotechnology
$36.88
Up+$0.60 (+1.65%)
Updated Aug 22, 2026, 3:32 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.81B
- P/E ratio
- -63.88
- Dividend yield
- 0.00%
- 52-week range
- $27.56 – $37.44
- Volume
- 329.45K
- Avg. volume
- 310.24K
Price performance
IMCR price history
1M range · 21 trading sessions · Daily adjusted prices
IMCR closed at $36.88 after 21 trading sessions, up 5.37% for the selected period.
- Last close
- $36.88
- Period change
- +5.37%
- Period low
- $32.43
- Period high
- $36.88
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $36.70 | $36.98 | $35.68 | $36.88 | 329.45K |
| Aug 20, 2026 | $36.60 | $36.60 | $35.08 | $36.28 | 590.25K |
| Aug 19, 2026 | $36.16 | $37.44 | $35.42 | $36.86 | 677.78K |
| Aug 18, 2026 | $35.09 | $36.44 | $34.775 | $36.02 | 620.06K |
| Aug 17, 2026 | $34.25 | $35.27 | $33.865 | $35.05 | 261.46K |
| Aug 14, 2026 | $34.02 | $34.39 | $33.50 | $34.21 | 195.19K |
| Aug 13, 2026 | $34.69 | $35.19 | $33.925 | $34.20 | 329.52K |
| Aug 12, 2026 | $34.33 | $34.87 | $34.13 | $34.74 | 352.96K |
| Aug 11, 2026 | $33.77 | $34.62 | $33.62 | $34.18 | 283.53K |
| Aug 10, 2026 | $33.71 | $34.28 | $33.52 | $33.98 | 301.78K |
| Aug 7, 2026 | $34.50 | $34.64 | $33.22 | $34.00 | 492.09K |
| Aug 6, 2026 | $32.84 | $34.58 | $32.47 | $34.50 | 572.98K |
| Aug 5, 2026 | $33.34 | $33.55 | $32.32 | $33.29 | 518.65K |
| Aug 4, 2026 | $32.90 | $33.64 | $32.03 | $33.24 | 576.25K |
| Aug 3, 2026 | $33.80 | $34.4613 | $32.23 | $32.43 | 645.65K |
| Jul 31, 2026 | $34.00 | $34.14 | $32.83 | $33.81 | 761.77K |
| Jul 30, 2026 | $33.26 | $33.91 | $33.02 | $33.87 | 213.13K |
| Jul 29, 2026 | $33.41 | $33.79 | $32.8401 | $33.42 | 192.3K |
| Jul 28, 2026 | $33.77 | $34.155 | $33.13 | $33.51 | 207.25K |
| Jul 27, 2026 | $35.06 | $35.87 | $33.77 | $33.77 | 329.13K |
| Jul 24, 2026 | $35.40 | $35.555 | $34.70 | $35.00 | 530.38K |
Latest IMCR news
The latest Smart Investors Daily articles mentioning IMCR.
Stock researchCompany · Overview
IMCR research
Overview
Company profile and research snapshot.
Company profile
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $48.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 21, 2026 | JP Morgan | Overweight | — |
| Aug 3, 2026 | Mizuho | Neutral | — |
| Apr 20, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 14, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 16, 2026 | Jefferies | Hold | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 6, 2026
Immunocore Holdings plc (IMCR) Q2 2026 Earnings Call Transcript
Immunocore Holdings plc (IMCR) Q2 2026 Earnings Call August 6, 2026 8:00 AM EDTCompany ParticipantsRyan BakerBahija Jallal - CEO & Executive...
ChartMill · Aug 6, 2026
Immunocore (NASDAQ:IMCR) Q2 Revenue Beats but EPS Misses, Shares Tumble
Immunocore Q2 revenue beat at $115.9M but EPS missed at -$0.02; shares fall 27% despite KIMMTRAK growth and pipeline catalysts.
Benzinga · Aug 6, 2026
Immunocore Hldgs Q2 EPS $(0.02) Misses $0.02 Estimate, Sales $115.927M Beat $110.374M Estimate
Immunocore Hldgs (NASDAQ:IMCR) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.02 by 200 percent. This is a 90 percent increase over losses of $(0.20) per share from the
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
